C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart D—Fda Action on Applications and Abbreviated Applications

21 C.F.R. § 314.107 (2026)

Date of approval of a 505(b)(2) application or ANDA

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1995–2025 71citing cases
At a glance

Courts have cited this section in 71 opinions since 1995, 5 of them in the last five years. The most litigated part is subsection (c)(1) (4 cases).

(a) General. A drug product may be introduced or delivered for introduction into interstate commerce when the 505(b)(2) application or ANDA for the drug product is approved. A 505(b)(2) application or ANDA for a drug product is approved on the date FDA issues an approval letter under § 314.105 for the 505(b)(2) application or ANDA.

(b) Effect of patent(s) on the listed drug. As described in paragraphs (b)(1) and (2) of this section, the status of patents listed for the listed drug(s) relied upon or reference listed drug, as applicable, must be considered in determining the first possible date on which a 505(b)(2) application or ANDA can be approved. The criteria in paragraphs (b)(1) and (2) of this section will be used to determine, for each relevant patent, the date that patent will no longer prevent approval. The first possible date on which the 505(b)(2) application or ANDA can be approved will be calculated for each patent, and the 505(b)(2) application or ANDA may be approved on the last applicable date.

(1) Timing of approval based on patent certification or statement. If none of the reasons in § 314.125 or § 314.127, as applicable, for refusing to approve the 505(b)(2) application or ANDA applies, and none of the reasons in paragraph (d) of this section for delaying approval applies, the 505(b)(2) application or ANDA may be approved as follows:

(i) Immediately, if the applicant certifies under § 314.50(i) or § 314.94(a)(12) that:

(A) The applicant is aware of a relevant patent but the patent information required under section 505(b) or (c) of the Federal Food, Drug, and Cosmetic Act has not been submitted to FDA; or

(B) The relevant patent has expired; or

(C) The relevant patent is invalid, unenforceable, or will not be infringed, except as provided in paragraphs (b)(3) and (c) of this section, and the 45-day period provided for in section 505(c)(3)(C) and (j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act has expired; or

(D) There are no relevant patents.

(ii) Immediately, if the applicant submits an appropriate statement under § 314.50(i) or § 314.94(a)(12) explaining that a method-of-use patent does not claim an indication or other condition of use for which the applicant is seeking approval, except that if the applicant also submits a paragraph IV certification to the patent, then the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(1)(i)(C) of this section.

(iii) On the date specified, if the applicant certifies under § 314.50(i) or § 314.94(a)(12) that the relevant patent will expire on a specified date.

(2) Patent information filed after submission of 505(b)(2) application or ANDA. If the holder of the approved NDA for the listed drug submits patent information required under § 314.53 after the date on which the 505(b)(2) application or ANDA was submitted to FDA, the 505(b)(2) applicant or ANDA applicant must comply with the requirements of § 314.50(i)(4) and (6) and § 314.94(a)(12)(vi) and (viii) regarding submission of an appropriate patent certification or statement. If the applicant submits an amendment certifying under § 314.50(i)(1)(i)(A)(4) or § 314.94(a)(12)(i)(A)(4) that the relevant patent is invalid, unenforceable, or will not be infringed, and complies with the requirements of § 314.52 or § 314.95, the 505(b)(2) application or ANDA may be approved immediately upon submission of documentation of receipt of notice of paragraph IV certification under § 314.52(e) or § 314.95(e). The 45-day period provided for in section 505(c)(3)(C) and (j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act does not apply in these circumstances.

(3) Disposition of patent litigation—(i) Approval upon expiration of 30-month period or 7 1/2 years from date of listed drug approval. (A) Except as provided in paragraphs (b)(3)(ii) through (viii) of this section, if, with respect to patents for which required information was submitted under § 314.53 before the date on which the 505(b)(2) application or ANDA was submitted to FDA (excluding an amendment or supplement to the 505(b)(2) application or ANDA), the applicant certifies under § 314.50(i) or § 314.94(a)(12) that the relevant patent is invalid, unenforceable, or will not be infringed, and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement within 45 days of receipt of the notice of certification from the applicant under § 314.52 or § 314.95, the 505(b)(2) application or ANDA may be approved 30 months after the later of the date of the receipt of the notice of certification by any owner of the listed patent or by the NDA holder (or its representative(s)) unless the court has extended or reduced the period because of a failure of either the plaintiff or defendant to cooperate reasonably in expediting the action; or

(B) If the patented drug product qualifies for 5 years of exclusive marketing under § 314.108(b)(2) and the patent owner or its representative or the exclusive patent licensee brings suit for patent infringement during the 1-year period beginning 4 years after the date of approval of the patented drug and within 45 days of receipt of the notice of certification from the applicant under § 314.52 or § 314.95, the 505(b)(2) application or ANDA may be approved at the expiration of the 7 1/2 years from the date of approval of the NDA for the patented drug product.

(ii) Federal district court decision of invalidity, unenforceability, or non-infringement. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the district court decides that the patent is invalid, unenforceable, or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity), the 505(b)(2) application or ANDA may be approved on:

(A) The date on which the court enters judgment reflecting the decision; or

(B) The date of a settlement order or consent decree signed and entered by the court stating that the patent that is the subject of the certification is invalid, unenforceable, or not infringed.

(iii) Appeal of Federal district court judgment of infringement. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the district court decides that the patent has been infringed, and if the judgment of the district court is appealed, the 505(b)(2) application or ANDA may be approved on:

(A) The date on which the mandate is issued by the court of appeals entering judgment that the patent is invalid, unenforceable, or not infringed (including any substantive determination that there is no cause of action for patent infringement or invalidity); or

(B) The date of a settlement order or consent decree signed and entered by the court of appeals stating that the patent that is the subject of the certification is invalid, unenforceable, or not infringed.

(iv) Affirmation or non-appeal of Federal district court judgment of infringement. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the district court decides that the patent has been infringed, and if the judgment of the district court is not appealed or is affirmed, the 505(b)(2) application or ANDA may be approved no earlier than the date specified by the district court in an order under 35 U.S.C. 271(e)(4)(A).

(v) Grant of preliminary injunction by Federal district court. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the district court grants a preliminary injunction prohibiting the applicant from engaging in the commercial manufacture or sale of the drug product until the court decides the issues of patent validity and infringement, and if the court later decides that:

(A) The patent is invalid, unenforceable, or not infringed, the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(3)(ii) of this section; or

(B) The patent is infringed, the 505(b)(2) application or ANDA may be approved as provided in paragraph (b)(3)(iii) or (iv) of this section, whichever is applicable.

(vi) Written consent to approval by patent owner or exclusive patent licensee. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the patent owner or the exclusive patent licensee (or their representatives) agrees in writing that the 505(b)(2) application or ANDA may be approved any time on or after the date of the consent, approval may be granted on or after that date.

(vii) Court order terminating 30-month or 7 1/2-year period. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the court enters an order requiring the 30-month or 7 1/2-year period to be terminated, the 505(b)(2) application or ANDA may be approved in accordance with the court's order.

(viii) Court order of dismissal without a finding of infringement. If before the expiration of the 30-month period, or 7 1/2 years where applicable, the court(s) enter(s) an order of dismissal, with or without prejudice, without a finding of infringement in each pending suit for patent infringement brought within 45 days of receipt of the notice of paragraph IV certification sent by the 505(b)(2) or ANDA applicant, the 505(b)(2) application or ANDA may be approved on or after the date of the order.

(4) Tentative approval. FDA will issue a tentative approval letter when tentative approval is appropriate in accordance with this section. In order for a 505(b)(2) application or ANDA to be approved under paragraph (b)(3) of this section, the applicant must receive an approval letter from the Agency. Tentative approval of an NDA or ANDA does not constitute “approval” of an NDA or ANDA and cannot, absent an approval letter from the Agency, result in an approval under paragraph (b)(3) of this section.

(c) Timing of approval of subsequent ANDA. (1) If an ANDA contains a paragraph IV certification for a relevant patent and the ANDA is not that of a first applicant, the ANDA is regarded as the ANDA of a subsequent applicant. The ANDA of a subsequent applicant will not be approved during the period when any first applicant is eligible for 180-day exclusivity or during the 180-day exclusivity period of a first applicant. Any applicable 180-day exclusivity period cannot extend beyond the expiration of the patent upon which the 180-day exclusivity period was based.

(2) A first applicant must submit correspondence to its ANDA notifying FDA within 30 days of the date of its first commercial marketing of its drug product or the reference listed drug. If an applicant does not notify FDA, as required in this paragraph (c)(2), of this date, the date of first commercial marketing will be deemed to be the date of the drug product's approval.

(3) If FDA concludes that a first applicant is not actively pursuing approval of its ANDA, FDA may immediately approve an ANDA(s) of a subsequent applicant(s) if the ANDA(s) is otherwise eligible for approval.

(d) Delay due to exclusivity. The Agency will also delay the approval of a 505(b)(2) application or ANDA if delay is required by the exclusivity provisions in § 314.108; section 527 of the Federal Food, Drug, and Cosmetic Act and § 316.31 of this chapter; section 505A of the Federal Food, Drug, and Cosmetic Act; or section 505E of the Federal Food, Drug, and Cosmetic Act. When the approval of a 505(b)(2) application or ANDA is delayed under this section and § 314.108; section 527 of the Federal Food, Drug, and Cosmetic Act and § 316.31 of this chapter; section 505A of the Federal Food, Drug, and Cosmetic Act; or section 505E of the Federal Food, Drug, and Cosmetic Act, the 505(b)(2) application or ANDA will be approved on the latest of the days specified under this section and § 314.108; section 527 of the Federal Food, Drug, and Cosmetic Act and § 316.31 of this chapter; section 505A of the Federal Food, Drug, and Cosmetic Act; or section 505E of the Federal Food, Drug, and Cosmetic Act, as applicable.

(e) Notification of court actions or written consent to approval. (1) The applicant must submit the following information to FDA, as applicable:

(i) A copy of any judgment by the court (district court or mandate of the court of appeals) or settlement order or consent decree signed and entered by the court (district court or court of appeals) finding a patent described in paragraph (b)(3) of this section invalid, unenforceable, or not infringed, or finding the patent valid and infringed;

(ii) Written notification of whether or not any action by the court described in paragraph (e)(1)(i) of this section has been appealed within the time permitted for an appeal;

(iii) A copy of any order entered by the court terminating the 30-month or 7 1/2-year period as described in paragraph (b)(3)(i), (ii), (vii), or (viii) of this section;

(iv) A copy of any written consent to approval by the patent owner or exclusive patent licensee described in paragraph (b)(3)(vi) of this section;

(v) A copy of any preliminary injunction described in paragraph (b)(3)(v) of this section, and a copy of any subsequent court order lifting the injunction; and

(vi) A copy of any court order pursuant to 35 U.S.C. 271(e)(4)(A) ordering that a 505(b)(2) application or ANDA may be approved no earlier than the date specified (irrespective of whether the injunction relates to a patent described in paragraph (b)(3) of this section).

(2) All information required by paragraph (e)(1) of this section must be sent to the applicant's NDA or ANDA, as appropriate, within 14 days of the date of entry by the court, the date of appeal or expiration of the time for appeal, or the date of written consent to approval, as applicable.

(f) Forty-five day period after receipt of notice of paragraph IV certification—(1) Computation of 45-day time clock. The 45-day clock described in paragraph (b)(3) of this section as to each recipient required to receive notice of paragraph IV certification under § 314.52 or § 314.95 begins on the day after the date of receipt of the applicant's notice of paragraph IV certification by the recipient. When the 45th day falls on Saturday, Sunday, or a Federal holiday, the 45th day will be the next day that is not a Saturday, Sunday, or a Federal holiday.

(2) Notification of filing of legal action. (i) The 505(b)(2) or ANDA applicant must notify FDA in writing within 14 days of the filing of any legal action filed within 45 days of receipt of the notice of paragraph IV certification by any recipient. A 505(b)(2) applicant must send the notification to its NDA. An ANDA applicant must send the notification to its ANDA. The notification to FDA of the legal action must include:

(A) The 505(b)(2) application or ANDA number.

(B) The name of the 505(b)(2) or ANDA applicant.

(C) The established name of the drug product or, if no established name exists, the name(s) of the active ingredient(s), the drug product's strength, and dosage form.

(D) A statement that an action for patent infringement, identified by court, case number, and the patent number(s) of the patent(s) at issue in the action, has been filed in an appropriate court on a specified date.

(ii) A patent owner or NDA holder (or its representative(s)) may also notify FDA of the filing of any legal action for patent infringement. The notice should contain the information and be sent to the offices or divisions described in paragraph (f)(2)(i) of this section.

(iii) If the 505(b)(2) or ANDA applicant, the patent owner(s), the NDA holder, or its representative(s) does not notify FDA in writing before the expiration of the 45-day time period or the completion of the Agency's review of the 505(b)(2) application or ANDA, whichever occurs later, that a legal action for patent infringement was filed within 45 days of receipt of the notice of paragraph IV certification, the 505(b)(2) application or ANDA may be approved upon expiration of the 45-day period (if the 505(b)(2) or ANDA applicant confirms that a legal action for patent infringement has not been filed) or upon completion of the Agency's review of the 505(b)(2) application or ANDA, whichever is later.

(3) Waiver. If the patent owner or NDA holder who is an exclusive patent licensee (or its representative(s)) waives its opportunity to file a legal action for patent infringement within 45 days of a receipt of the notice of certification and the patent owner or NDA holder who is an exclusive patent licensee (or its representative(s)) submits to FDA a valid waiver before the 45 days elapse, the 505(b)(2) application or ANDA may be approved upon completion of the Agency's review of the NDA or ANDA. FDA will only accept a waiver in the following form:

(Name of patent owner or NDA holder who is an exclusive patent licensee or its representative(s)) has received notice from (name of applicant) under (section 505(b)(3) or 505(j)(2)(B) of the Federal Food, Drug, and Cosmetic Act) and does not intend to file an action for patent infringement against (name of applicant) concerning the drug (name of drug) before (date on which 45 days elapse). (Name of patent owner or NDA holder who is an exclusive patent licensee) waives the opportunity provided by (section 505(c)(3)(C) or 505(j)(5)(B)(iii) of the Federal Food, Drug, and Cosmetic Act) and does not object to FDA's approval of (name of applicant)'s (505(b)(2) application or ANDA) for (name of drug) with an approval date on or after the date of this submission.

(g) Conversion of approval to tentative approval. If FDA issues an approval letter in error or a court enters an order requiring, in the case of an already approved 505(b)(2) application or ANDA, that the date of approval be delayed, FDA will convert the approval to a tentative approval if appropriate.

[81 FR 69655, Oct. 6, 2016]
The 20 cases that cite 21 C.F.R. § 314.107 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
REDJoblove v. Barr Labs. Inc., 466 F.3d 187 (2d Cir. 2005).
cites § 314.107 6×subsections: (c)(1)cited by 132 cases
Abrogated by F.T.C. v. Actavis, Inc. on other grounds: 17 citing opinions limit it to other grounds and 5 say abrogated outright.
Where it cites § 314.107
“See 21 C.F.R. § 314.107 (c)(1) (1995). This so-called “successful defense” requirement was challenged in 1997 in two separate lawsuits.”
The case’s holding
A patent settlement agreement does not violate antitrust laws if it does not extend the patent monopoly beyond the scope of the patent protection.
Later courts cite it for
“it is within the court's discretion to deny leave to amend implicitly by not addressing the request when leave is requested informally in a brief filed in opposition to a motion to dismiss.” · 22 citing courts
2
GREENMova Pharm. Corp. v. Shalala, 140 F.3d 1060 (D.C. Cir. 1998).
cites § 314.107 5×cited by 309 cases
The case’s holding
An agency regulation exceeds its statutory authority if it adds a successful-defense requirement to a statute providing exclusivity based on commercial marketing or a court decision regarding patent invalidity.
Later courts cite it for
“who in practice can be expected to police the interests that the statute protects.” · 17 citing courts
3
GREENMylan Pharm., Inc. v. Shalala, 81 F. Supp. 2d 30 (D.D.C. 2000).
cites § 314.107 5×cited by 89 cases
Where it cites § 314.107
“21 C.F.R. § 314.107 (e) (1999). Thus, when a district court decision favorable to the generic manufacturer is appealed, the FDA calculates the 180-day exclusivity period from the date that the court of appeals affirms.”
The case’s holding
A plaintiff alleging non-recoverable monetary loss must demonstrate that the injury is more than simply irretrievable and is serious in its effect on the business.
Later courts cite it for
“strong showing that economic loss would significantly damage its business above and beyond a simple diminution in profits.” · 9 citing courts
4
GREENAndrx Pharm., Inc. v. Biovail Corp. Int'l, 256 F.3d 799 (D.C. Cir. 2001).
cites § 314.107 3×cited by 94 cases
Where it cites § 314.107
“37-38 (citing 21 C.F.R. § 314.107 (c)(i) (1997)). We rejected the FDA’s “successful defense” regulation in Mova Pharm.”
The case’s holding
A potential competitor has antitrust standing if it alleges intent and preparedness to enter the market through probable regulatory approval.
Later courts cite it for
“the kind of injury the antitrust laws were intended to prevent.” · 3 citing courts
5
GREENMeijer, Inc. v. Biovail Corp., 533 F.3d 857 (D.C. Cir. 2008).
cites § 314.107 3×cited by 83 cases
Where it cites § 314.107
“§ 355 (j)(5)(B)(iv)(II)(dd)(BB);' see also 21 C.F.R. § 314.107 (b)(3). In June 1998 Andrx filed an ANDA seeking approval to market Diltiazem HC1 under the name Taztia; Andrx included a Paragraph IV certification both challenging the validity of Biovail’s U.”
The case’s holding
An amended complaint fails to relate back if the original pleading does not adequately notify defendants of the basis for liability later advanced in the amendment.
Later courts cite it for
“the underlying question is whether the original complaint adequately notified the defendants of the basis for liability the plaintiffs would later advance in the amended complaint.” · 20 citing courts
6
GREENDr. Reddy's Labs., Inc. v. Thompson, 302 F. Supp. 2d 340 (D.N.J. 2003).
cites § 314.107 7×subsections: (c)(1) 2× (e)(1)cited by 12 cases
Where it cites § 314.107
“Final approval is effective only after the FDA issues a final approval letter, 21 C.F.R. § 314.107 (b)(3)(v), and changed conditions may necessitate delay in the final approval of a tentatively approved ANDA.”
Later courts cite it for
“be able to sell its rights to . . . exclusivity” · 2 citing courts
7
GREENIn re Ciprofloxacin Hydrochloride Antitrust Litig., 261 F. Supp. 2d 188 (E.D.N.Y. 2003).
cites § 314.107 3×cited by 50 cases
Where it cites § 314.107
“; see also 21 C.F.R. § 314.107 . Factual Background 5 (1) Bayer manufactures and distributes Ci-pro, a broad spectrum antibiotic that is prescribed for various infections and is dispensed in tablet, liquid and intravenous forms.”
The case’s holding
Settlement agreements resolving patent litigation do not constitute a per se antitrust violation when the patent rights are the primary source of market exclusion.
Later courts cite it for
“even in the traditional context, implicit consideration flows from the patent holder to the alleged infringer.” · 3 citing courts
8
GREENPharmachemie B.V. v. Barr Labs., Inc., 276 F.3d 627 (D.C. Cir. 2002).
cites § 314.107 2×cited by 105 cases
Where it cites § 314.107
“§ 355(j)(5)(B)(iii); 21 C.F.R. § 314.107 (f)(2). If a patent infringement action is timely brought, the ANDA can be approved only upon the expiration of a thirty-month period, unless this period is altered by the court or a decision of that court.”
The case’s holding
A case is moot if events transpire such that a decision will neither presently affect the parties' rights nor have a more-than-speculative chance of affecting them in the future.
Later courts cite it for
“a reasonable degree of likelihood that the issue will be the basis of a continuing controversy between the two parties.” · 4 citing courts
9
GREENMylan Labs., Inc. v. Thompson, 332 F. Supp. 2d 106 (D.D.C. 2004).
cites § 314.107 7×cited by 7 cases
Where it cites § 314.107
“§ 355 (j)(5)(B)(iii); 21 C.F.R. § 314.107 (f)(2). “The patent holder is, of course, free to sue the applicant for infringement .”
10
GREENMylan Labs., Inc. v. Tommy G. Thompson, 389 F.3d 1272 (D.C. Cir. 2005).
cites § 314.107 2×cited by 64 cases
Where it cites § 314.107
“” Letter 1 at 11 (citing 21 C.F.R. § 314.107 (b)(3)(v); 3 Barr *1278 Labs.”
The case’s holding
An agency's interpretation of a statute it administers receives deference if the interpretation rests on a permissible construction of the law.
Later courts cite it for
“decision made no great legal leap but relied in large part on its previous determination of the same or similar issues and on its own regulations.” · 2 citing courts
11
GREENMylan Labs. Ltd. v. Food & Drug Admin., 910 F. Supp. 2d 299 (D.D.C. 2012).
cites § 314.107 3×cited by 20 cases
Where it cites § 314.107
“See 21 C.F.R. § 314.107 (c)(3). 8 The Court concludes, however, that Mylan has raised this argument too late.”
The case’s holding
A first ANDA applicant keeps 180-day marketing exclusivity when an FDA-reviewed change in approval requirements, not the applicant's own conduct, caused its failure to obtain tentative approval within 30 months.
Later courts cite it for
“applicant makes a paragraph iii certification, the fda may grant tentative approval of the anda, to be made effective on the date the patent expires.” · 2 citing courts
12
GREENSandoz, Inc. v. Food & Drug Admin., 439 F. Supp. 2d 26 (D.D.C. 2006).
cites § 314.107 2×cited by 22 cases
Where it cites § 314.107
“§ 355 (j)(5)(B)(iv) (2002); 21 C.F.R. § 314.107 (c)(1). As this Court has explained: In order to encourage generic drug makers to incur the potentially substantial litigation costs associated with challenging pioneer drug makers’ patents, -the Hatch-Waxman Amendments provide an…”
13
GREENGalderma Labs., L.P. v. Teva Pharm. USA, Inc., 290 F. Supp. 3d 599 (N.D. Tex. 2017).
cites § 314.107 1×cited by 27 cases
Where it cites § 314.107
“See 21 C.F.R. § 314.107 (b)(3)(i)(A). If the NDA holder fails to bring suit within 45 days, the ANDA applicant may file a declaratory judgment action to adjudicate its paragraph IV challenge.”
Later courts cite it for
“most district courts within this circuit have imposed the burden of proving that venue is proper on the plaintiff once a defendant has objected to the plaintiff's chosen forum.” · 11 citing courts
14
GREENMylan Pharm., Inc. v. Sebelius, 856 F. Supp. 2d 196 (D.D.C. 2012).
cites § 314.107 3×cited by 8 cases
Where it cites § 314.107
“) Second, Mylan argues that Teva USA was not “actively pursuing approval of [its ANDA]” as required by 21 CFR § 314.107 (c)(3), and therefore, the FDA should have approved Mylan’s application instead.”
15
GREENAstra Aktiebolag v. Andrx Pharm., Inc., 222 F. Supp. 2d 423 (S.D.N.Y. 2002).
cites § 314.107 1×cited by 63 cases
Where it cites § 314.107
“§ 355 (j)(5)(B)(iii); 21 C.F.R. § 314.107 (f)(2). If a patent infringement action is timely brought, final marketing approval of the ANDA cannot occur before expiration of thirty months or a decision of a court.”
The case’s holding
A patentee may sue for direct infringement under 35 U.S.C. § 271(e)(2)(A) when a generic applicant submits an ANDA for a drug use covered by the patent.
Later courts cite it for
“methodology was transposed from one area to a completely different context, and there is no independent research supporting the transposition.” · 3 citing courts
16
cites § 314.107 2×cited by 15 cases
Where it cites § 314.107
“21 C.F.R. § 314.107 (c)(l)-(2) (only first-filer eligible for exclusivity period); 180-Day Generic Drug Exclusivity for Abbreviated New Drug Applications, 64 Fed.”
Later courts cite it for
“the plaintiff bears the initial burden of showing that the defendant's conduct 'had an actual adverse effect on competition as a whole in the relevant market.” · 1 citing court
17
GREENValley Drug Co. v. Geneva Pharm., Inc., 344 F.3d 1294 (11th Cir. 2003).
cites § 314.107 1×cited by 61 cases
Where it cites § 314.107
“3, 1994) (adopting successful defense regulation as a final rule, codified at 21 C.F.R. § 314.107 ). If Zenith's ANDA were ready for approval before Geneva successfully defended Abbott’s infringement suit, then the ANDA would be approved without the 180-day delay.”
The case’s holding
The presence of a reverse payment in a patent settlement does not automatically transform an otherwise lawful agreement into an unlawful antitrust violation.
Later courts cite it for
“we review a district court's grant of summary judgment de novo, applying the same legal standards applied by the district court.” · 10 citing courts
18
GREENBiovail Corp. Int'l v. Hoechst Aktiengesellschaft, 49 F. Supp. 2d 750 (D.N.J. 1999).
cites § 314.107 2×cited by 30 cases
Where it cites § 314.107
“In Mova, the Court of Appeals for the District of Columbia Circuit held that the FDA regulation, 21 C.F.R. § 314.107 (c)(1), was unenforceable because it was inconsistent with the plain language of 21 U.”
The case’s holding
At the Rule 12(b)(6) stage, courts construe all facts for the plaintiff, and where a contract provision's interpretation or ambiguity is not yet clear, it is too early to resolve it.
Later courts cite it for
“it is simply too early to determine whose interpretation of the relevant provision is correct or even whether the provision is sufficiently ambiguous to warrant referral to the fact-finder.” · 3 citing courts
19
GREENMylan Pharm., Inc. v. Henney, 94 F. Supp. 2d 36 (D.D.C. 2000).
cites § 314.107 2×cited by 27 cases
Where it cites § 314.107
“§ 355 (j)(5)(B)(iii); 21 C.F.R. § 314.107 (f)(2). 1 If a patent action is brought within 45 days, however, the ANDA will not be approved until at least 30 months from the date the affected parties, i.”
The case’s holding
Consolidation under Rule 42(a) is proper for any or all common matters in issue, even where the plaintiffs seek different forms of relief.
Later courts cite it for
“the plaintiffs' requests for different forms of relief do not vitiate the propriety of consolidation, but rather, consolidation is proper to any or all matters in issue which are common.” · 2 citing courts
20
GREENKaiser Found. Health Plan, Inc. v. Abbott Labs., Inc., 552 F.3d 1033 (9th Cir. 2009).
cites § 314.107 1×cited by 41 cases
Where it cites § 314.107
“21 C.F.R. § 314.107 (e) (1989). 2 . The patent examiner spelled out “K-A-NG-I” in his deposition.”
The case’s holding
Under the sham exception to Noerr-Pennington immunity, a suit is immune from antitrust liability where it has a plausible argument on which it could have prevailed, even if most suits fail.
Later courts cite it for
“had a plausible argument on which it could have prevailed” · 3 citing courts

Show all 71 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199520102025

One bar per year. Tallest: 6 cases in 2002. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.21D.C. Cir.12Fed. Cir.6S.D.N.Y.62d Cir.5D.N.J.4D. Del.3S.D. Fla.3

The 8 courts with the most citing cases, of 15 courts in all.

By subsection
(c)1 case
EKR Therapeutics, Inc. v. Sun Pharm. Indus., Ltd., 633 F. Supp. 2d 187 (D.N.J. 2009).
(c)(1)4 cases
Joblove v. Barr Labs. Inc., 466 F.3d 187 (2d Cir. 2005).“See 21 C.F.R. § 314.107 (c)(1) (1995). This so-called “successful defense” requirement was challenged in 1997 in two separate lawsuits.”
Dr. Reddy's Labs., Inc. v. Thompson, 302 F. Supp. 2d 340 (D.N.J. 2003).“Final approval is effective only after the FDA issues a final approval letter, 21 C.F.R. § 314.107 (b)(3)(v), and changed conditions may necessitate delay in the final approval of a tentatively approved ANDA.”
In re Tamoxifen Citrate Antitrust Litig., 429 F.3d 370 (2d Cir. 2005).
Joblove, Allied Servs. v. Barr Labs. Inc., 429 F.3d 370 (2d Cir. 2005).
(e)(1)2 cases
Dr. Reddy's Labs., Inc. v. Thompson, 302 F. Supp. 2d 340 (D.N.J. 2003).
Pharmachemie B V v. Henney, Jane, 284 F.3d 125 (D.C. Cir. 2002).

Show all 71 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com